Cited by 321Pharmacology and Obesity TreatmentDiabetes Treatment and ManagementRegulation of Appetite and Obesity

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Metformin Decreases Food Consumption and Induces Weight Loss in Subjects with Obesity with Type II Non‐Insulin‐Dependent Diabetes

Open access
Lee, Amy, Morley, John E.·1998·Obesity Research

Abstract

Metformin often promotes weight loss in patients with obesity with non‐insulin‐dependent diabetes mellitus (NIDDM). The mechanism may be attributed to decreased food intake. This study has tested the effect of metformin on satiety and its efficacy in inducing weight loss. Twelve diet‐treated NIDDM women with obesity were randomly given two dose levels (850 mg or 1700 mg) of metformin or placebo at 0800 for three consecutive days followed by a meal test on the third day on three occasions using a 3times3 Latin square design. The number of sandwich canapes eaten in three consecutive 10‐minute periods beginning at 1400 hours was used to quantitate food intake, and the level of subjective hunger was rated just before the sandwich meal with a linear analogue hunger rating scale at 1400 after a 6‐hour fast. The prior administration of metformin produced a reduction in calorie intake after each of the two doses of metformin treatment. The 1700‐mg metformin dose had the most marked appetite suppressant action. Similarly, hunger ratings were significantly lowered after metformin, and the effect was most pronounced after the administration of 1700 mg of metformin. To assess the efficacy of metformin in reducing bodyweight, 48 diet‐treated NIDDM women with obesity who had failed to lose weight by diet therapy were first placed on a 1200‐kcal ADA (American Diabetes Association) diet before being randomized to receive either metformin (850 mg) or placebo twice daily in a double‐blind fashion for 24 weeks. A 4‐week single‐blind placebo lead‐in period preceded and a 6‐week single‐blind placebo period followed the 24‐week double‐blind treatment period. Subjects treated with metformin continued to lose weight throughout 24 weeks of treatment; their mean maximum weight loss was 8 kg greater than that of the placebo group, with corresponding lower HbA1C and fasting blood glucose levels at the end of the active treatment period. These results indicate that metformin decreases calorie intake in a dose‐dependent manner and leads to a reduction in bodyweight in NIDDM patients with obesity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/j.1550-8528.1998.tb00314.x

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 5

  1. Klein W., 1991, Sulfonylurea‐metformin combination versus sulfonylurea‐insulin‐combination in secondary failures of sulfonylurea monotherapy, Diabetes Metab., 17, 235
  2. Leatherdale BA, 1986, Acute antihyperglycemic effect of metformin without alteration of gastric emptying, IRCS Med Sci., 14, 1085
  3. Lee A., 1997, The effect of acarbose on body weight regulation, Diabetes., 46, 257A
  4. Rissanen A., 1997, Long‐term weight management in obesity with orlistat, a new gastrointestinal lipase inhibitor, Diabetes., 46, 87A
  5. Schwartz MW, 1992, Insulin and the central regulation of energy balance: Update, Endocr Rev., 13, 387

Cited by

Sorted by citations

See all 321

Metadata

Authors
Lee, A., & Morley, J. E.
Affiliations
Saint Louis University (US)
Corresponding author
Lee, Amy
Venue
Obesity Research
Publisher
Wiley
Published
1998-01
Volume
6
Issue
1
Pages
47-53
ISSN
  • 1071-7323 (ISSN-L)
  • 1550-8528
OpenAlex
W2092252523
Cited by
320
References
40
Citations by year
2026: 6 · 2025: 5 · 2024: 12 · 2023: 14 · 2022: 14 · 2021: 10 · 2020: 12 · 2019: 12 · 2018: 14 · 2017: 19 · 2016: 15 · 2015: 10 · 2014: 22 · 2013: 12 · 2012: 15
FWCI
5.13
Type
journal article
Language
en
Open access
Locations
  • Obesity Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
metformin, obesity, type 2 diabetes, weight loss, dietary intake, satiety, appetite suppression, hunger, dose-dependent effects, dietary therapy, glycemic control, HbA1c, fasting blood glucose
MeSH terms
Adult, Blood Glucose, Energy Intake, Diabetes Mellitus, Diabetes Mellitus, Type 2, Double-Blind Method, Eating, Female, Glycated Hemoglobin, Humans, Hunger, Hypoglycemic Agents, Metformin, Middle Aged, Obesity, Weight Loss

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review